Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2019.12.12

Sai Nxt

Sai Life Sciences announces Sai Nxt, an initiative to transform the organization into a new generation CDMO

Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced Sai Nxt, an organization-wide initiative aimed at transforming the company into a new generation CDMO. Guided by the insights and feedback from its customers, the company is investing upwards of US $ 150 million over the period between 2019 and 2023 as a part of Sai Nxt, with a focus on three key areas :

  1. People & culture
  2. Processes & automation
  3. Infrastructure & scientific capabilities

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences said, “Sai Nxt marks a transformative phase in our journey. Our growth over the years has essentially been driven by our scientific capabilities and customer focus. Raising the bar further, Sai Nxt will help us better serve the growing demand from global innovator pharma and biotech companies for speed and flexibility, with an assurance of compliance and dependability.”

Built on the foundation of partnership, Sai Life Sciences has grown to become one of India’s most trusted CDMOs. Coinciding with the completion of 20 years since its inception, Sai Nxt is the transformative lever aimed to propel the organization in the next phase of its growth.

Sai Nxt initiatives

  1. People & Culture: Expanding scientific talent pool, inducting top-notch global scientific and leadership talent, role-based integrated online training, shop floor transformation, nurturing culture of excellence
  2. Processes & Automation: Process simplification, strengthening governance systems, electronic manufacturing records, IT systems integration, foundation for seamless data capture across operations, leveraging latest technologies (RPA, IOT, AI / ML, AR/ VR) for innovation and intelligence
  3. Infrastructure & Capabilities: Biology lab in Cambridge (MA, USA), Process R&D lab in Manchester (UK), Integrated Discovery and Development campus, expanded suite of technology platforms, early phase delivery facility, flexible manufacturing with 2.5x capacity, advanced safety & quality systems

Through Sai Nxt, the company aims to significantly expand and upgrade its R&D and manufacturing facilities, deepen scientific & technological capabilities, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

Share article

More News

2025.10.31

Sai Life Sciences becomes a signatory to the UN Women’s Empowerment Principles

Sai Life Sciences has joined the global community of signatories to the Women’s Empowerment Principles (WEPs) — an initiative established by UN Women and the UN Global Compact (UNGC). The WEPs serve as a global framework for businesses to advance gender equality and empower women in the workplace, marketplace, and community. By becoming a WEPs […]
Read more

2025.10.27

Sai Life Sciences set to double Process R&D capacity with new facility in Hyderabad

Hyderabad, India, October 27, 2025: Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO), today announced the groundbreaking for a new CMC Process R&D Center at its integrated R&D campus in Hyderabad. Scheduled for completion by September 2026, the facility will double the […]
Read more

2025.10.08

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators

Manchester/Hyderabad, October 08, 2025: Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API […]
Read more

2025.10.06

Unlocking Chemical Frontiers: IIT Bombay Prof, Debabrata Maiti at Sai Life Sciences

As part of Sai Life Sciences’ efforts to foster knowledge exchange and bring leading voices from niche areas of science and technology to its teams, the company recently hosted Prof. Debabrata Maiti from the Indian Institute of Technology (IIT) Bombay at its R&D campus in Hyderabad for a day of scientific exchange and dialogue. The […]
Read more

2025.09.18

Sai Life Sciences opens dedicated facility for Veterinary APIs in Bidar, India

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for veterinary API production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. The new […]
Read more